Image

Evaluation of an IV Insulin Electronic Glucose Management System Using FDA Cleared Feature of EREI (Estimated Residual Extracellular Insulin) to Prevent Severe Hypoglycemia

Objective

This retrospective review examines effects of the specialized EndoTool EREI (estimated residual extracellular insulin) adjustment feature on glycemic control of patients receiving intravenous insulin.

Setting

Cohort of 30 community hospitals.

Results
  • With the EREI adjustment feature enabled, median time to goal was 3.3 hours for a range of 140-180 mg/dL and 135-155 mg/dL.
  • With the EREI adjustment feature enabled, incidence of severe hypoglycemia <40 mg/dL was 0.009% of blood glucose readings for a range of 140-180 mg/dL and .0007% of blood glucose readings for a range of 135-155 mg/dL.
Conclusions

Use of the specialized EndoTool EREI adjustment feature creates the potential to eliminate severe hypoglycemia while achieving target glucose levels and provides additional safety to the dosing of intravenous insulin without the human error and confusion associated with paper protocols.

Authors

W. Patrick Burgess, PhD, MD; Laurel Fuqua, RN, MSN.

Source

Presented at International Conference on Advanced Technologies & Treatments for Diabetes. Published in Diabetes Technology & Therapeutics, Volume 22, Issue S1, p584.

Year

2020